Pilot Safety and Blood Immune Cell Transcriptional Profiling Study of Anakinra Plus the Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients

Trial Profile

Pilot Safety and Blood Immune Cell Transcriptional Profiling Study of Anakinra Plus the Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Anakinra (Primary) ; Capecitabine; Eribulin; Paclitaxel; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 07 Jun 2016 Results of safety and immunologic activity of anakinra (n=11) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 13 Jan 2016 Planned End Date changed from 1 Jul 2014 to 1 Dec 2016 as per ClinicalTrials.gov record.
    • 13 Jan 2016 Planned primary completion date changed from 1 Jun 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top